Prostate cancer is the second most common malignant tumor in men and its incidence is closer to skin cancer, melanoma, and the second leading cause of cancer death. The National Cancer Institute (NCI), one of the largest National Institutes of Health in the United States, issued a notice concerning the research on the prevention of this disease.
Recent advances in the fields of chemoprevention and preventive oncology prostate are related to two key areas: the most promising agents to prevent prostate cancer and the most important biological markers for early detection. Among the actors mentioned as possible candidates for prevention are the anti-androgens, anti-estrogens, retinoids, nonsteroidal antiinflammatory drugs, differentiating agents, tyrosine kinase inhibitors and antioxidants, among others. Read the rest of this entry »